Alvotech Dossier
|
SectorHealth Care IndustryDrug Manufacturers - Specialty & Generic Beta (adjusted)0.40 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $5.80Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $2.1B Enterprise Value $3.2B Shares Outstanding 356.8M diluted Moat Rating Narrow Next Earnings Date11 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Alvotech is a commercial-stage biosimilar specialist with a robust pipeline of 30 biosimilar candidates and five already approved and marketed products globally. Despite recent regulatory setbacks at its Reykjavik manufacturing facility that led to FDA Complete Response Letters (CRLs), the company remains a high-growth play. Management has actively addressed the FDA's CMC requirements and resubmitted BLAs for key candidates AVT05 and AVT06 in Q2 2026. With a strong network of global commercial partners (such as Teva and Sandoz) and a clear path to positive cash flow by Q4 2026, the stock represents an attractive speculative opportunity following its recent valuation pullback. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$4.00 Mean target$5.75 High · most bullish analyst$9.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The bear case reflects further regulatory delays or additional CRLs from the FDA regarding the Reykjavik facility. This would push U.S. commercial launches of AVT05 and AVT06 into 2027 or later, keeping revenues at the lower end of guidance ($650M) and delaying the transition to positive cash flow. Continued high cash burn would require further dilutive equity raises or expensive debt financing, putting pressure on the stock price. Base CaseCentral scenario The base case assumes Alvotech successfully resolves the FDA's CMC observations at its Reykjavik facility, leading to the approval and launch of AVT05 and AVT06 in the U.S. by late 2026. Topline revenue is expected to meet management's 2026 guidance of $650M to $700M, driven by continued commercial momentum of AVT02 (Humira biosimilar) and AVT04 (Stelara biosimilar) in Europe and Canada. The company achieves positive cash flow in Q4 2026, supported by the $152M capital raise in June 2026, which stabilizes the balance sheet and funds ongoing R&D. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |